Advanced searches left 3/3

Fatty Liver Disease - Springer Nature

Summarized by Plex Scholar
Last Updated: 13 September 2022

* If you want to update the article please login/register

Treatment of rheumatoid arthritis with conventional, targeted and biological disease-modifying antirheumatic drugs in the setting of liver injury and non-alcoholic fatty liver disease

For every ten cases of alanine aminotransferase elevation in a clinical trial, it is predicted that one case of more serious liver injury will occur if the investigated drug is widely available. Biologic disease-modifying antirheumatic drugs and targeted synthetic are less likely to cause liver disease. Non-alcoholic fatty liver disease research has provided insight into a pre-existing liver disease that can be exacerbated by medication. Diabetes and obesity could pose an additional challenge to opioid-induced liver disease. This narrative review explores the specifics and prevention of DILI in RA and treatment options involving biological therapy and tsDMARDs.

Source link: https://doi.org/10.1007/s00296-022-05143-y


Long-term cardiovascular outcomes differ across metabolic dysfunction-associated fatty liver disease subtypes among middle-aged population

The new metabolic dysfunction-related fatty liver disease guidelines for diabetes mellitus, obesity/obese, or lean/normal weight with metabolic dysfunction have all been identified as three main subtypes. We investigated whether long-term cardiovascular disease outcomes in the MAFLD subgroups differed over time. Using a BARD score of u2265 2. 169,433 new cardiovascular disease events occurred during a median follow-up period of 10. 0 years. In the OW-MAFLD, lean-MAFLD, and DM-MAFLD groups, respectively, multivariable-adjusted hazard ratios for cardiovascular disease cases were 1. 16, 1. 23, and 1. 82, respectively, with the non-MAFLD group as a reference. Regardless of metabolic abnormalities or comorbidities, participants with lean-MAFLD or DM-MAFLD had a higher cardiovascular risk than those with OW-MAFLD. In each MAFLD subtype, the presence of advanced liver fibrosis was strongly associated with a higher risk of cardiovascular disease in each MAFLD subtype. Conclusions Long-term cardiovascular disease results among the MAFLD subtypes varied.

Source link: https://doi.org/10.1007/s12072-022-10407-7


Evaluation of Six Noninvasive Methods for the Detection of Fibrosis in Chinese Patients with Obesity and Nonalcoholic Fatty Liver Disease

Purpose Nonalcoholic fatty liver disease is the most common chronic liver disease in the world, and liver fibrosis has been shown to be correlated with liver disease-related events and total mortality in liver disease. Compared were the results of FIB-4, APRI, m-APRI, BARD, NFS, and SWE in the evaluation of significant or advanced liver fibrosis in Chinese patients with obesity and NAFLD. In the diagnosis of significant and advanced liver fibrosis in patients with obesity and NAFLD, APRI and SWE were superior to the other techniques. Conclusions Weight and ALT are independent risk factors for liver fibrosis progression in NAFLD patients. Significant and advanced fibrosis of NAFLD in Chinese patients with obesity are predicted by SWE and APRI.

Source link: https://doi.org/10.1007/s11695-022-06251-1


The triglyceride glucose-body mass index: a non-invasive index that identifies non-alcoholic fatty liver disease in the general Japanese population

Some studies have shown that triglyceride glucose-body mass index had a positive correlation with NAFLD. However, evidence indicating the effectiveness of its diagnostic function in patients with suspected NAFLD is limited. We wanted to see if TyG-BMI was reliable in detecting NAFLD in the general Japanese population in this research. Methods An cross-sectional analysis of 14,280 people who underwent a comprehensive health examination was carried out. The presence of NAFLD could be effectively determined by using TyG-BMI's high cutoff, as the positive predictive value of the estimation and validation groups is 70% and 71%, respectively. Using 183,730 Chinese non-obese participants, AUC was 0. 874 for external validation. Conclusions In conclusion, the present study developed and validated a simple, non-invasive, and cost-effective method to properly distinguish participants with and without NAFLD in the Japanese population, effectively distinguishing participants with and without NAFLD, demonstrating ultrasonography for diagnosing NAFLD in a large number of people.

Source link: https://doi.org/10.1186/s12967-022-03611-4


Anti-obesity Medications for the Management of Nonalcoholic Fatty Liver Disease

The purpose of this study was to summarize the evidence on the effects of anti-obesity drugs on NAFLD, especially the hepatic histology. Orlistat and some glucagon-like receptor analogs, including liraglutide and semaglutide, have positive effects on hepatic steatosis and inflammation, but not fibrosis. In addition, sodium-glucose cotransporter-2 inhibitors and farnesoid X receptor inhibitors have shown healthful results in both NAFLD and obesity, but no one has been approved for either condition.

Source link: https://doi.org/10.1007/s13679-022-00474-0


Association between lower plasma adiponectin levels and higher liver stiffness in type 2 diabetic individuals with nonalcoholic fatty liver disease: an observational cross-sectional study

Purpose Little is known about the connection between plasma adiponectin levels and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus. We investigated whether there was a correlation between lower plasma adiponectin levels and the presence/severity of NAFLD in people with T2DM. Methods We cross-sectionally recruited 79 men with non-insulin-treated T2DM and no identified liver diseases who had been outpatient for the past six months and who underwent both ultrasonography and Fibroscan-measured liver stiffness, a three-month illness affecting liver stiffness. Compared to those without NAFLD, patients with hepatic steatosis alone, and those with hepatic steatosis and coexisting significant fibrosis had lower adiponectin levels. Bottom plasma adiponectin levels are closely associated with the presence and severity of T2DM in men with T2DM, indicating a role for adiponectin in NAFLD development and progression.

Source link: https://doi.org/10.1007/s42000-022-00387-6


Association of hypertriglyceridemic waist phenotype with non-alcoholic fatty liver disease: a cross-sectional study in a Chinese population

Introduction In a middle- to senior-aged Chinese population, the aim of this research was to establish the relationship between hypertriglyceridemic waist phenotype and non-alcoholic fatty liver disease. Methods: The following nine phenotypes were included in this cross-sectional study: NWNT: normal waist; NWET: elevated waist; and hypertriglycerides: NWMT: normal waist; and hypertriglycerides: u2013normal waist; and obese waists, as follows: a triglycerides; and hypotriglycerides: conventional waist; and hypertriglycerides: the normal waist; and hypertriglycerides To determine the correlations between HTGW phenotype and NAFLD, a logistic regression analysis was conducted. HTGW had a higher incidence of NAFLD, diabetes, and hypertension than the other three subgroups. The WTI was 90. 1, when the maximum area under the curve was 0. 6. 99, and the equivalent sensitivity and specificity were 90. 6 and 59. 5%, respectively. HTGW phenotype is strongly associated with NAFLD and can be used as a reference point for NAFLD screening.

Source link: https://doi.org/10.1007/s42000-022-00374-x


Periodontal Disease and Nonalcoholic Fatty Liver Disease: New Microbiome-Targeted Therapy Based on the Oral–Gut–Liver Axis Concept

Purpose of Review The aim of this article is to analyze the growing body of evidence reveals the negative effects of periodontal disease on nonalcoholic fatty liver disease, the most common chronic liver disease worldwide. In NAFLD, intestinal translocation of periodontopathic bacteria may be responsible for enteral diffusion, and gut microbiome dysbiosis caused by enteral translocation of periodontopathic bacteria may be involved. The disruption of the gut epithelial barrier, which may promote leakage of microbial products and metabolites into the portal circulation, is one factor that is thought to connect the gut microbiome to NAFLD. Both the gut dysbiosis and NAFLD can be responsible for Porphyromonas gingivalis, a common periodontopathic bacteria, in the pathogenesis of both the gut dysbiosis and NAFLD can be caused by various pathways. The importance of the oralu2013gut u2013liver axis in NAFLD's pathogenesis is increasing, and future research on microbiome-targeted therapy to improve periodontal disease-related gut dysbiosis is warranted.

Source link: https://doi.org/10.1007/s40496-022-00312-1


Antibody to hepatitis B virus core antigen positivity is a predictor of non-alcoholic fatty liver disease severity

We wanted to determine the effects of a limited alcohol intake and of occult hepatitis B virus infections on the severity of NAFLD. NAFLD patients were randomly admitted to the outpatients clinic of a referral liver unit from January 1st, 2018 to December 31st, 2019. Patients had a mean BMI of 28. 5 kg/m2, and the majority of them had metabolic and cardiovascular disorders [258 patients had insulin resistance/diabetes, 249 dyslipidemia, and 200 arterial hypertension]. Moderate alcohol intake was not related to severe NAFLD at both FIB-4 and transient elastography tests, according to a multivariate analysis. Anti-HBc positivity was a risk associated with advanced fibrosis at FIB-4 score testing, but moderate alcohol intake was not related to severe NAFLD at FIB-4 and transient elastography studies. According to the report, moderate alcohol intake has no influence on NAFLD severity, and that OBI may have no effect on NAFLD outcomes.

Source link: https://doi.org/10.1007/s11739-022-02971-5


Non-invasive diagnosis and staging of non-alcoholic fatty liver disease

Although the majority of NAFLD patients will never experience liver-related diseases, the majority of patients will never experience liver disease, end-stage liver disease, or hepatocellular carcinoma have appeared, only 53% of patients developed to cirrhosis, end-stage liver disease, or hepatocellular carcinoma. Patients with advanced fibrosis are at risk of developing cardiovascular and cirrhosis-related complications in NAFLD patients with advanced fibrosis. Liver biopsy has been widely used for the evaluation of hepatic steatosis and fibrosis stage. In NAFLD, this comprehensive review explores the advantages and disadvantages of NITs in determining steatosis and advanced fibrosis. The clinical implications of using NITs to identify and monitor NAFLD patients are also discussed.

Source link: https://doi.org/10.1007/s42000-022-00377-8

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions

* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions